Lilly's Zepbound Outperforms Novo's Wegovy in Weight Loss Study, Boosting Stock
TL;DR Summary
Eli Lilly has emerged victorious in a head-to-head clinical trial against Novo Nordisk, showcasing the effectiveness of its weight loss treatment. This development marks a significant moment in the competitive market for first-generation weight loss drugs, where both companies have been leading players.
- Lilly beats Novo in bellwether head-to-head weight loss study Endpoints News
- Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial CNBC
- Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Investors | Eli Lilly and Company
- Eli Lilly’s stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial MarketWatch
- Eli Lilly Zepbound More Effective Than Novo’s Wegovy, Study Finds. Lilly Stock Gains. Barron's
Reading Insights
Total Reads
0
Unique Readers
14
Time Saved
0 min
vs 1 min read
Condensed
23%
56 → 43 words
Want the full story? Read the original article
Read on Endpoints News